Genmab — Februar 2016
-
Der står jokeren er Humax-TF-ADC
-
Ellers intet nyt
-
Enig, men det nævnes som jokeren, at der kan komme nyt om dette
-
jokeren må da helt klart være 2016 guidance. ifm regnskabet har vi vist aldrig rigtig set kliniske data alligevel...
-
at breake data på nuværende tidspunkt vil da være helt tosset. Den slags skal ske til Asco for maximum effekt
-
jep - og så oven i købet forum for solide tumorer
-
anyway - der er primary completion på tf-adc til oktober, så chancen for at se noget lige med det samme er vel begrænset
-
Florian huserer på børsen play lige nu - hvis nogen mangler et confidence boost før regnskabet
-
her er link - http://play.borsen.dk/social/56c214de725ed7540a0ce688
-
-
spændende. Udvidelser af klinikken er mere end velkomne
-
MYELOMA INTERGROUP FRANCOPHONE DU in collaboration with Janssen initiated another phase III trial to evaluate daratumumab in combination with bortezomib, thalidomide and dexamethasone, as front-line therapy in approximately 1080 patients with multiple myeloma who are candidates for stem cell transplantation (IFM 2015-01; HO131; 54767414MMY3006; EudraCT2014-004781-15; NCT02541383). The trial will be conducted in collaboration with the and the Dutch-Belgian Cooperative Trial Group for Haematology
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind